Dynamics of sodium retention in preascitic cirrhotic rats assessed through parathyroid hormone injection. by Sansoe, G et al.
INTRODUCTION
Liver cirrhosis is complicated by renal sodium retention,
which leads, eventually, to the ascitic stage of clinical
decompensation. Before ascites development, sodium retention
already occurs despite normal or even increased glomerular
filtration rate (GFR) (1-6). The tubular segment where increased
sodium reabsorption occurs in pre-ascitic cirrhosis is still
debated.
Animals with preascitic cirrhosis and sodium retention have
normal fluid delivery from the proximal convoluted tubule to the
Henle’s loop (7-10). Lithium clearance, which is an established
index of distal tubular delivery of fluid, is significantly reduced
in standing preascitic cirrhotic patients, but is normal in supine
ones (11-13). Yet patients with compensated cirrhosis while
reclining show sodium retention in some tubular segment of the
nephron (6, 12, 14).
Plasma levels of renin and aldosterone are either normal or
slightly decreased in early cirrhosis (6, 15-17). This might mean
that increased sodium reabsorption in aldosterone-sensitive
nephron segments is unlikely, but mineralocorticoid-receptor
antagonists delay ascites development (18), which led to the
hypothesis that aldosterone sensitivity might be in some way
increased in preascitic cirrhosis (19).
At least one alternative hypothesis to explain preascitic
sodium retention may be suggested. In preascitic cirrhotic rats,
Jonassen and colleagues described a selective hypertrophy of the
thick ascending limb (TAL) of Henle’s loop in the outer medulla
(8, 9). Those rats showed sodium retention at baseline, increased
natriuretic responses to furosemide, and increased medullary
interstitial sodium concentration (20, 21). Furthermore, rats with
CCl4-induced liver cirrhosis have increased content of Na+-K+-
2Cl– cotransporters in the TAL of Henle’s loop (22).
Summarizing, so far increased preascitic sodium retention in the
Henle’s loop has been repeatedly suspected but never
demonstrated.
Parathyroid hormone (PTH) exerts physiological effects on
the regulation of tubular electrolyte and water transport in the
kidney. PTH infusion increases diuresis and natriuresis (23, 24),
and primary hyperparathyroidism is associated with polyuria,
polydipsia, and reduced urinary concentrating capacity (25, 26).
PTH and hypercalcemia reduce the contents of Na+-K+-2Cl–
cotransporters (BSC-1) in the ascending limb of Henle’s loop
and of aquaporin-2 (AQP2) water channels in the collecting duct
(24, 27).
Intravenous calcium loading leads to larger natriuresis and
aquaresis in compensated cirrhotic patients than in healthy
controls (14). This means that at least part of the sodium
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Extracellular Ca++ stimulates membrane-bound calcium-sensing receptors (CaRs). CaRs stimulation leads to PGE2-
mediated decrease in protein content of Na+-K+-2Cl– co-transporters (BSC-1) in the thick ascending limb (TAL) of
Henle’s loop and of aquaporin 2 (AQP2) water channels in collecting ducts. Parathyroid hormone (PTH) increases CaRs
and decreases BSC-1 and AQP2 tubular content. To assess the Ca++-dependent diuretic system in preascitic cirrhosis, we
evaluated renal function, hormonal status, PGE2 urinary excretion, and renal content of BSC-1 and CaRs in three groups
of rats: control rats received s.c. 5% glucose solution; two groups of rats with CCl4-induced preascitic cirrhosis received
either s.c. glucose solution or five s.c. doses of 10 mcg/Kg PTH (one dose every 12 hours) prior to study. Cirrhotic rats,
when compared to controls, showed reduced urine volume and sodium excretion; moreover, western blot analysis
revealed reduced CaRs and increased BSC-1 protein content in cirrhotic rat kidneys. S.c. administration of PTH
normalized urine and sodium excretion in cirrhotic rats and also increased renal plasma flow, PGE2 urinary excretion,
and free-water clearance. Finally, PTH reduced BSC-1 and augmented CaRs content in cirrhotic rat kidneys. In
conclusion, in preascitic cirrhosis sodium retention is associated with down-regulation of renal CaRs and up-regulation
of tubular Na+-K+-2Cl- co-transporters. PTH returns these biomolecular changes, along with sodium and urine
excretions, to normality, suggesting that exaggerated sodium reabsorption occurs primarily in the Henle’s loop in
preascitic cirrhosis.
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retention in pre-ascitic cirrhosis occurs in Ca++-sensitive
segments of the nephron (i.e. in the Henle’s loop). The diuretic
effect shown in calcium-loaded preascitic cirrhotic patients was
attributed to stimulation of extracellular calcium/polyvalent
cation-sensing receptors (CaRs) (14). This is reasonable
because, in rats with experimental preascitic liver cirrhosis and
sodium retention, stimulation of CaRs with calcimimetic agents
returns sodium and free-water excretion to normality (28). In the
kidney, CaRs are located mainly in the TAL of Henle’s loop and
in the collecting duct (29). In the TAL of Henle’s loop, CaRs
stimulation inhibits sodium-potassium-chloride co-transport and
leads to increased natriuresis (24, 30-34).
PTH, calcium, and CaRs compose an actual Ca++-dependent
diuretic system, the activity of which might be deranged in
preascitic cirrhosis with sodium retention. We hypothesize that,
in pre-ascitic cirrhosis, the Henle’s loop might be a key
contributor to sodium retention. To dissect the actual
contribution of Henle’s loop to sodium retention in rats with
experimental preascitic cirrhosis, we have evaluated the renal
biomolecular and functional effects that subcutaneous
administration of PTH may cause through modulation of the
content of CaRs and Na+-K+-2Cl– cotransporters (BSC-1) in
renal tubules.
MATERIAL AND METHODS
Experiments in rats were performed in compliance with the
procedures outlined in the Italian Ministry of Health guidelines
(no. 86/609/EEC) and according to the Principles of Laboratory
Animal Care (NIH no. 85-23, revised in 1985). The University
of Torino ethics committee specifically approved this study.
Studies were performed on male adult Wistar rats with
preascitic cirrhosis and related control animals (Harlan Italy,
Udine, Italy). Both groups were fed ad libitum with standard
chow and water. Preascitic cirrhosis was induced by carbon
tetrachloride (CCl4) (Riedel de Haen, Sigma-Aldrich, Seelze,
Germany) chronically administered by gavage twice weekly as
described elsewhere (28, 35). Cirrhotic rats were studied 9
weeks after starting CCl4 administration, when cirrhosis was
clearly developed (35) (Fig. 1). Control rats were studied
following a similar period of standardized diet.
Groups of rats
Human PTH1-34 (Bachem Distribution Services GmbH,
Weil am Rhein, Germany) was dissolved in 5% glucose solution
(vehicle) and administered subcutaneously to ten cirrhotic rats
(group G3) in five timely spaced doses (one dose every 12 hours
for 2 days before the study day) of 0.5 ml vehicle containing 10
mcg/Kg PTH. Eight control rats (group G1) and ten cirrhotic rats
(group G2) were injected subcutaneously with the same volumes
of vehicle alone.
Study protocol
On the study day, the rats were anaesthetized as described
elsewhere (36). Blood was sampled (time 0) by cardiac puncture
(0.3 cc) and inulin (IN) 10% (w/v) (Laevosan-Gesellschaft,
Linz/Donau, Austria) plus para-aminohippurate (PAH) 20%
(w/v) (Nephrotest, BAG Gmbh, Munich, Germany) were
administered into the caudal vein as a priming bolus (0.14 ml/kg
and 0.03 ml/kg, respectively) followed by a continuous infusion
of 0.09 ml/kg/h inulin and 0.025 ml/kg/h PAH for 150 min, in
order to assess glomerular filtration rate (GFR) and renal plasma
flow (RPF) at different times by means of their respective
steady-state plasma clearances (CIN and CPAH) (28, 37, 38).
The steady state technique implies these advantages over the
urine collection clearance method: catheterization of the bladder
and exact timing of serum and urine samples are unnecessary,
less analytical work is needed, and more urine is available for
further testing (38).
After 90 min of IN and PAH infusions (i.e. when the steady-
state plasma levels of IN and PAH were reached) (28, 37),
laparotomy was performed, the urinary bladder was emptied,
and a clamp was positioned on the urethral orifice. Cardiac
blood was then sampled (time 1) to assess basal values of CIN
and CPAH, and then vehicle alone was injected as a single bolus
(1 ml) into the right femoral vein of all rats (groups G1-G3).
Cardiac blood was then sampled (0.3 cc) at precise intervals (20
min) for 1 hour (times 2, 3 and 4) to measure plasma osmolality
and concentrations of inulin, PAH, sodium, potassium, and
calcium. At each blood withdrawal, the volume of blood
withdrawn was replaced with an equal volume of i.v. saline (28).
Blood samples withdrawn at time 4 (i.e. 60 min after the
injection of vehicle) were also used to measure plasma
concentrations of PTH, vasopressin (AVP), plasma renin activity
(PRA), aldosterone (A), norepinephrine (N), aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
albumin and total bilirubin. At time 4, after collecting from the
bladder the urine produced during the 60 min after vehicle
administration, rats were killed by exsanguination through the
aorta. This urine was then used to measure its osmolality and the
excretion of sodium, potassium, and PGE2.
CaRs and BSC-1 protein concentrations in rat kidneys
Membrane fractions were prepared from kidneys removed
from five rats in each experimental group (G1-G3) and the total
protein content was assessed using Bradford Assay as described
previously (28). Equal amounts of proteins (30 µg) were
separated by SDS-PAGE and electrotransferred on nitrocellulose
membrane (GE-Healthcare Europe, Milano, Italy). Membranes
were probed with rabbit anti-CaRs (PA1-934, ABR Affinity
BioReagents, Golden, CO, USA) and rabbit-anti BSC-1
(NKCC21-A, Alpha Diagnostic International, San Antonio, TX,
USA) primary antibodies, followed by incubation with anti-
rabbit IgG/HRP-conjugated secondary antibody (BioRad,
Hercules, CA, USA).
Proteins were detected with Clarity Western ECL substrate
(BioRad) and quantified by densitometry using analytic software
(Quantity-One, Bio-Rad). Results were normalized with respect
to b-actin densitometric value.
Kidney CaRs and BSC-1 indirect immunofluorescence
Indirect immunofluorescence was performed in a humidified
chamber at room temperature, essentially as described elsewhere
(28, 39), on kidney cryostat sections (6 µm thick). Mouse
monoclonal anti-CD31, an endothelial marker (BD-Pharmingen,
Erembodegem, Belgium), and rabbit polyclonal anti-CaRs and
anti-BSC-1 primary antibodies were used (28, 40).
Plasma and urine analyses
Plasma and urinary concentrations of electrolytes, and IN
and PAH concentrations in plasma were measured as described
elsewhere (41, 42). AVP and PTH systemic concentrations were
measured on EDTA plasma by RIA (Buhlmann Laboratories AG,
Postfach, Switzerland). PRA was measured using RIA for
angiotensin I (Renin Maia Kit, Biodata, Rome, Italy).
Aldosterone was evaluated by RIA (Coat-A-Count Aldosterone
kit, Diagnostic Products Corporation, Los Angeles, CA, USA),
and norepinephrine was measured as described elsewhere (43,
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44). Urine samples were assayed for PGE2 concentrations by
ELISA (Neogen, Lexington, KY, USA). Plasma AST, ALT,
albumin and total bilirubin levels were determined by means of
automated Roche/Hitachi Cobas equipment.
Calculations
Sodium clearance (CNa) and potassium clearance (CK) were
calculated through the formula:
Cx = (U-x x V)/P-x
where U-x is the urinary concentration of x, P-x is the
plasma concentration of x, and V is the urinary output (ml/min).
Inulin clearance (CIN) and para-aminohippurate clearance
(CPAH) were calculated through the steady-state plasma
clearance formula as:
Cx = Infusion rate (x)/ssP-x
where ssP-x is the steady-state plasma concentration of x.
CIN and CPAH were taken as measures of GFR and RPF (37,
38). Filtered sodium load (FlNa) was derived, following Boer et
al. (45), as:
FlNa = Sodium plasma concentration (P-Na) x CIN
Fractional sodium excretion (FENa) and fractional
potassium excretion (FEK) were calculated, respectively, from
the ratios of CNa and CK to CIN x 100.
Free-water clearance (F-WCl) was calculated, following
Rose and Post (46), through the formula:
F-WCl = V – Cosm
where V is the urinary output (ml/min); Cosm is the osmolar
clearance, which was computed via the usual formula:
Cosm = (Uosm x V)/Posm
where Uosm and Posm are urine and plasma osmolalities,
respectively.
Finally, in order to evaluate aldosterone function on the
distal tubular nephron, the trans-tubular concentration ratio of
potassium in the cortical collecting duct (TTKR) was calculated
according to the following formula (47, 48):
TTKR = [K+]urine /(U/P)osm
[K+]serum
This parameter provides a semiquantitative reflection of the
ratio of [K+] in the tubule fluid to that in the plasma of the
adjacent vessels in the cortical collecting duct, an aldosterone-
dependent segment of the tubular nephron.
All renal function parameters were derived by computing the
mean of three determinations of osmolality, inulin, PAH,
sodium, potassium, and calcium in plasma during the 60 min
urine collection period (blood sampling times 2, 3, and 4).
Morphological liver studies
Livers were removed from all rats receiving CCl4, and
hepatic tissue samples for light microscopy were placed in
buffered 4% formaldehyde solution (pH 7.4). The sections were
stained with hematoxylin and eosin to assess fibrosis. Silver-
impregnated liver sections were used to observe portal-central or
central-central bridging fibrosis.
Statistical analysis
Results are expressed as means ± S.D. All comparisons
among groups of rats were made by one-way ANOVA test,
followed by the Bonferroni test. The analyses were processed by
the SPSS® 13.0 software (Chicago, USA), using a significance
level of 5%.
RESULTS
Morphological liver studies
Micronodular cirrhosis with hepatocellular necrosis and
steatosis was found in all the livers removed from CCl4-treated
rats (Fig. 1).
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Fig. 1. Cirrhosis induction program. To induce preascitic liver cirrhosis with CCl4 the protocol described by Proctor and Chatamra was
used (28, 35). This method involves two administrations a week of carbon tetrachloride by gavage and its effects are highly
predictable: after 9 weeks micronodular cirrhosis is evident, rats are devoid of ascites (as assessed by laparotomy) and portal pressure
is increased to about 10 mmHg; after 11 weeks rats are ascitic and their mean portal pressure is 24 mmHg; after 14 weeks they develop
renal failure and eventually die.
Content and immunostaining of renal CaRs and BSC-1
A comparative analysis of the membrane fraction of renal
tissue homogenate showed that CaRs protein content was
significantly reduced in cirrhotic vs. control animals, and protein
content of BSC-1 was significantly increased in cirrhotic rats
(Fig. 2). Protein content of CaRs and BSC-1 returned to control
values in cirrhotic rats pre-treated with s.c. PTH (Fig. 2). CaRs-
and BSC-1-positive tubular cells were identified in the TAL of
Henle’s loop of normal and cirrhotic rat kidneys, as shown
previously (28). CaRs were located in the sub-endothelial layers
of kidney medullary arterioles of cirrhotic rats (Fig. 3). In
control and cirrhotic rats, CaRs were also located in medullary
collecting ducts, as previously shown (28).
Hormonal status (Table 1)
Treatment with s.c. PTH had no effects on PRA, A, AVP, and
N plasma levels in cirrhotic animals. PTH-treated cirrhotic rats
(G3) had significantly higher plasma PTH concentrations and
higher urinary excretion rate of PGE2 when compared to the
untreated cirrhotic group (G2). Increased PGE2 urinary excretion
is expected when hypercalcemia stimulates CaRs.
Renal function (Table 2)
Compared to control animals (G1), cirrhotic rats belonging
to G2 showed reduced urine volume and absolute and fractional
excretions of sodium. Free-water clearance was lower in
cirrhotic animals than in control rats, and RPF was higher in
cirrhotic rats than in controls, at baseline. In cirrhotic rats, s.c.
PTH significantly improved urine volume, absolute and
fractional excretion of sodium and potassium, which means that
the TAL of Henle’s loop is affected, free-water clearance, which
means the collecting duct is affected, and renal plasma flow. The
values of TTKR were equal in control and cirrhotic rats. PTH did
not affect GFR in cirrhotic rats, and, as expected, PTH
significantly increased plasma Ca++ levels in cirrhotic rats.
DISCUSSION
In experimental preascitic cirrhosis, retention of sodium and
fluid is associated with increased contents of Na+-K+-2Cl–
cotransporters in the TAL of Henle’s loop. Sodium retention is
also associated with decreased contents of CaRs (the targets of
extracellular Ca++ and calcimimetic drugs) in Henle’s loop and
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Fig. 2. Western blotting of CaRs and BSC-1 in kidney. Western blots of representative experiments showing CaRs and Na+-K+-Cl–
cotransporter (BSC-1) levels in the membrane fractions of kidneys of controls, cirrhotic rats, and cirrhotic rats treated with s.c. PTH;
c: control; cir: cirrhosis; cir + PTH: cirrhosis treated with PTH. b-actin is used as proteins loading control. Histograms report mean ±
S.D. (five rats in each group) of densitometric analysis of CaRs and BSC-1 kidney content, normalized for b-actin. CaRs are
significantly reduced and BSC-1 significantly increased in the membrane fraction of renal tissue homogenate from cirrhotic animals.
collecting ducts (Fig. 2). PTH administration restores the
physiological protein content of CaRs and BSC-1, and this
increases urinary sodium and water excretion of cirrhotic rats up
to the values measured in controls (Table 2). It is reasonable to
say that perhaps little sodium retention would occur in this early
stage of experimental preascitic cirrhosis if tubular content of
CaRs and, mostly, BSC-1 were normal.
In this study, aldosterone function was assessed through the
computation of the trans-tubular concentration ratio of
potassium in the cortical collecting duct (TTKR) (47, 48).
TTKR, which reflects the ratio between K+ concentrations in the
tubule fluid and in the plasma of the adjacent vessels, was equal
in control and cirrhotic rats. This indicates that
mineralocorticoid-mediated hyperstimulation of tubular sodium
re-absoprtion in exchange with potassium secretion has not
occurred yet at this early stage of compensated cirrhosis. In other
words, increased sodium re-absorption in the Henle’s loop
precedes aldosterone-dependent sodium retention.
Subtle interactions between PTH systemic concentrations
and renin-angiotensin-aldosterone system (RAAS) activity have
been repeatedly described. For instance, infusion of angiotensin
II or aldosterone causes significant increase in the rate of PTH
secretion in human health and disease (49, 50); more
importantly, in healthy human subjects short-term PTH infusion
stimulates renin release and aldosterone secretion (51, 52), but
also increases the rate of renal hydroxilation of vitamin D,
which, in turn, may negatively regulate renin expression and
RAAS activity (50, 53). On the whole, in this study PTH
administration to cirrhotic rats caused a slight, statistically
insignificant, increase of both PRA and plasma aldosterone,
along with the natriuretic effects due to BSC-1 down-regulation.
Once again, this underlines the modest, if any, role of
aldosterone in the control of sodium handling in this stage of
cirrhotic disease.
PTH exclusive capacity to down-regulate BSC-1 and to up-
regulate CaRs was extremely useful to ascertain the dynamic
connections between the expression of the above proteins and
the patterns of tubular sodium handling. No other hormone can
modulate expression of CaRs and sodium channels in the tubular
nephron so promptly. Moreover, the choice of experimental
animal models is the only available option to study the dynamics
of expression of tubular sodium channels since it would be
unethical and dangerous to submit human cirrhotic patients to
repeated administrations of PTH.
This dynamic approach led to the conclusion that excessive
sodium retention takes place in the Henle’s loop of preascitic
cirrhotic rats. Previous literature had already suggested the
existence of such a mechanism of sodium retention in cirrhotic
rats (8, 21, 22, 28) based on the following findings: i) the TAL of
Henle’s loop is hypertrophic; ii) the natriuretic response to
furosemide and the medullary interstitial sodium concentration
are increased. Moreover, in patients with compensated cirrhosis,
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Fig. 3. CaRs in the wall of renal arterioles. Intense CaRs indirect immunofluorescence staining in the sub-endothelial layers (white
arrow) of renal arterioles located in the kidney medulla of cirrhotic rats. CD31 is a marker of endothelial cells (green arrows).
Magnification ×200.
the natriuretic responses to intravenous calcium loading are larger
than in controls (14) and aldosterone-independent sodium
retention takes place after the proximal convoluted tubule (6, 54).
There are analogies between the effects of PTH and
intravenous calcium loading (14), and this indicates that the
results presented in this study depend on the systemic
hypercalcemia induced by PTH. This also means that the
stimulation of CaRs in Henle’s loop and collecting duct, as
recently shown with the use of calcimimetic agents (28),
represents the actual trigger leading to the normalization of
sodium and fluid excretion in experimental preascitic cirrhosis.
Following the studies of Wang and associates (24), we chose
to inject a moderate dose of PTH to avoid early death of cirrhotic
rats due to excessive hypercalcemia. Yet this PTH dose increased
the urinary excretion of PGE2 (Table 1), the second messenger
generated after specific stimulation of CaRs (32), and caused
natriuresis and aquaresis (Table 2).
PTH injection in cirrhotic rats also caused a considerable
renal vasodilatation (Table 2). This was due to the large amount
of CaRs located in the sub-endothelial layers of renal arterioles
of the outer medulla (Fig. 3). This renal vasodilatation might be
useful in the advanced stages of cirrhosis, when renal
vasoconstriction leads to reduced GFR (55, 56).
Our results may also suggest a method of investigation of
two apparently unrelated processes: the hypercalciuria of
mineralocorticoid escape (57) and the tubular pattern of sodium
handling in chronic renal failure (CRF).
Mineralocorticoid escape indicates the occurrence of
reduced reabsorption of sodium in aldosterone-independent
tubules when the kidney faces chronically elevated levels of
plasma aldosterone. The hypercalciuria that coincides with
aldosterone escape might trigger decreased tubular sodium re-
absorption in the Henle’s loop and compensatory natriuresis.
Further on, increased expression of CaRs in peripheral blood
monocytes of patients with diabetes mellitus and peripheral
artery disease (58) might mean that this calcium-dependent
homeostatic mechanism is already somehow operative in that
clinical setting.
The already established association of CRF and systemic
down-regulation of CaRs (59, 60), suggests the explanation of a
common clinical observation: CRF is characterized by low GFR
and increased fractional excretion of sodium, while functional
renal failure (FRF) in liver cirrhosis is characterized by low GFR
and avid tubular sodium retention with low fractional sodium
excretion. The secondary hyperparathyroidism occurring in CRF
(61), but not in cirrhotic FRF, might contribute to the completely
different tubular handling of sodium that is found in these two
diseases.
In conclusion, in sodium-retaining preascitic cirrhotic rats
we confirmed increased content of Na+-K+-2Cl– cotransporters in
the TAL of Henle’s loop and down-regulation of renal CaRs, the
receptors that mediate Ca++-dependent diuresis. The injection of
PTH restored the physiological content of these tubular proteins
and returned renal sodium handling to normal. In this context,
the action of parathyroid hormone-related peptide (PTHrP) (62)
or exogenous compounds that affects both PTH and renal tubular
function (e.g. genistein) (63) would be worth some experimental
focus.
The findings described in this study represent experimental
evidence to support the hypothesis that sodium retention in
preascitic cirrhosis occurs first in the TAL of Henle’s loop and
later in aldosterone-dependent tubular segments. A third
mechanism of sodium retention, increased reabsorption in the
proximal convoluted tubule, is operative in preascitic cirrhotic
patients while standing (11, 12). This paves the way to potential
new strategies of prevention of ascites: orally active
calcimimetic agents (28, 61) or oral calcium supplement (14),
due to their diuretic, aquaretic and renal vasodilating properties,
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     G1 (n= 8)           G2 (n= 10)            G3 (n=10)         
Plasma AVP (pg/ml)              98 ± 57   104 ± 32               85 ± 41             
PRA (ng/ml/h)               20 ± 1           18 ± 2               21 ± 8           
Plasma A (ng/ml)   2.1 ± 1.9                   2.9 ± 3.1               3.1 ± 1.8 
Plasma N (pg/ml)  118 ± 71       142 ± 91   132 ± 64
Plasma PTH (pg/ml)    1.8 ± 0.8             2.0 ± 0.4             3.6 ± 0.5a
Urinary PGE2   2.0 ± 1.3   1.5 ± 0.1                   6.9 ± 2.2a
   (ng/h) 
Plasma AST (U/ml)  31 ± 21    52 ± 27b    59 ± 33b
Plasma ALT (U/ml)  38 ± 21    61 ± 22b    65 ± 38b
Plasma albumin (g/dl)          3.7 ± 1.2   2.6 ± 0.9b   2.4 ± 0.7b
Plasma bilirubin (mg/dl)      0.2 ± 0.04  2.8 ± 0.03b  3.0 ± 0.09b
Data are means ±S.D. G1: control rats; G2: cirrhotic rats; G3: cirrhotic rats receiving s.c. PTH. a P<0.05 vs. G2; b P<0.05 vs. G1 (one-
way ANOVA, followed by the Bonferroni test).
Table 1. Hormonal plasma and urine determinations in different groups of rats.
might represent further means to delay ascites development
when administered chronically in patients with compensated
cirrhosis.
Abbreviations: A: aldosterone; AQP2: aquaporin 2; AST:
aspartate aminotransferase; ALT: alanine aminotransferase;
AVP: vasopressin; BSC-1: Na+-K+-2Cl– cotransporter; CCl4:
carbon tetrachloride; CaRs: extracellular calcium/polyvalent
cation-sensing receptors; CIN: inulin clearance; CK: potassium
clearance; CNa: sodium clearance; CPAH: para-aminohippurate
clearance; CRF: chronic renal failure; FEK: fractional excretion
of potassium; FENa: fractional excretion of sodium; FlNa:
filtered sodium load; FRF: functional renal failure; F-WCl:
free-water clearance; GFR: glomerular filtration rate; IN:
inulin; N: norepinephrine; PAH: para-aminohippurate; PRA:
plasma renin activity; PTH: parathyroid hormone; PTHrP:
parathyroid hormone-related peptide; RAAS: renin-
angiotensin-aldosterone-system; RPF: renal plasma flow; SDS:
sodium dodecyl sulfate; TAL: thick ascending limb of Henle’s
loop; TTKR: trans-tubular concentration ratio of potassium in
the cortical collecting duct.
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